Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston says worst is over with automatic share sell-off

This article was originally published in Clinica

Executive Summary

Boston Scientific saw its share price hit a 52-week low on Friday (October 10) as heavy trading of its stock continued through to the end of the week. A significant portion of the trading was due to the automatic sales of shares owned by the company's co-founders Pete Nicholas and John Abele, and was not a reflection of the company's performance, Boston has stressed. The involuntary sell-off was triggered by recent events, including the bankruptcy of Lehman brothers, caused by the turbulent financial markets. As of the close of market on Friday, around 31 million shares in aggregate has been sold last week through the automatic sell-off. Boston said that they may be additional involuntary selling of the co-founders shares over the next several weeks, but it believes the majority of these sales has already occurred. Boston's share price sunk as low as $6.34 on Friday, before rebounding a little to close at $7.31.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT041278

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel